Overview

Prevention of C.Difficile Infections With Oral Vancomycine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

Status:
Not yet recruiting

Trial end date:
2025-07-01

Target enrollment:

Participant gender:

Summary

Clostridium difficile (CD) infection are an important cause of morbi-mortality in patients undergoing allogeneic hematopoietic stem cell transplant (HSCT). The VANCALLO trial aims at evaluating oral vancomycine reducing the risk of CD infection relying on a placebo controlled 1:1 randomized design, including one interim analysis.

Phase:

Phase 3

Details

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Collaborator:

GIRCI Ile de France

Treatments:

Vancomycin